Mometasone furoate (9α,21‐dichloro‐11β,17α –dihydroxy‐16α‐methyl‐pregna‐1,4‐diene‐3,20‐dione‐17‐(2′) furoate) is a chemical compound, corticosteroid, 17-ester furoate of mometasone, shows less affinity for dermal cells than epidermal cells and esterification at position 17 increases the lipophilicity of mometasone. This chemical compound has the effect of reaching a therapeutic concentration in the skin without being toxic.

It is a white to whitish powder practically insoluble in water, slightly soluble in octanol and moderately soluble in ethyl alcohol.

Its properties are:

• anti-inflammatory
• vasoconstrictive
• antipruriginous

Significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that Mometasone furoate sinus implants may play an important role in management of recurrent nasal polyps (1).

The first-line drugs for the pharmacotherapy of allergic rhinitis are, generally, corticosteroids, and treatment with Mometasone furoate nasal spray has been shown to be effective (2).

After the fifth day after tonsillectomy surgery in children, pain generally increases because it coincides with a time of intense wound inflammation. To relieve this pain, Mometasone furoate in the form of nasal spray has demonstrated analgesic effect and thus clinical importance to overcome this problem (3).

Asthma is a chronic inflammatory disease that causes significant morbidity and mortality. Inhaled corticosteroids are the preferred initial treatment for this disorder. For patients with persistent asthma who require treatment with an inhaled corticosteroid, mometasone furoate is an excellent therapeutic choice (4).

Mometasone furoate studies

Molecular Formula: C₂₇H₃₀Cl₂O₆

Molecular Weight : 521.4 g/mol

CAS: 83919-23-7

UNII 04201GDN4R

EC Number: 

DSSTox Substance ID: DTXSID4023333

MDL number  MFCD00866003

PubChem Substance ID 329823374

NACRES: NA.24

Synonims: 

• 9α,21-dichloro-11β-hydroxy-16α-methyl 3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
• (11β,16α)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
• Nasonex
• Asmanex
• Danitin
• (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate

References_____________________________________________________________

(1) Kern RC, Stolovitzky JP, Silvers SL, Singh A, Lee JT, Yen DM, Iloreta AMC Jr, Langford FPJ, Karanfilov B, Matheny KE, Stambaugh JW, Gawlicka AK; RESOLVE II study investigators. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol. 2018 Apr;8(4):471-481. doi: 10.1002/alr.22084.

(2) Shikh EV, Eremenko NN, Arefev KI. Farmakoterapiya allergicheskogo rinita: pozitsiya klinicheskogo farmakologa [Pharmacotherapy of allergic rhinitis: position of a clinical pharmacologist. Vestn Otorinolaringol. 2021;86(3):118-126. Russian. doi: 10.17116/otorino202186031118.

(3) Unsal O, Akpinar M, Bozkurt G, Soytas P, Ekici M, Turk B, Coskun BU. Nasal Sprays Containing Mometasone Furoate for Relief of Post-Adenotonsillectomy Pain in Children: A Prospective Controlled Study. Sisli Etfal Hastan Tip Bul. 2021 Mar 17;55(1):101-107. doi: 10.14744/SEMB.2020.75735.

(4) Fausnight TB, Craig TJ. Mometasone furoate dry powder inhaler for the treatment of asthma. Expert Opin Pharmacother. 2011 Dec;12(17):2707-12. doi: 10.1517/14656566.2011.630390.